Ballentine Partners LLC Makes New $263,000 Investment in Smith & Nephew SNATS, Inc. $SNN

Ballentine Partners LLC bought a new stake in Smith & Nephew SNATS, Inc. (NYSE:SNN) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 8,573 shares of the medical equipment provider’s stock, valued at approximately $263,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Hexagon Capital Partners LLC boosted its position in Smith & Nephew SNATS by 63.3% during the 1st quarter. Hexagon Capital Partners LLC now owns 1,047 shares of the medical equipment provider’s stock valued at $30,000 after purchasing an additional 406 shares during the period. Richards Merrill & Peterson Inc. grew its position in shares of Smith & Nephew SNATS by 500.0% during the first quarter. Richards Merrill & Peterson Inc. now owns 1,200 shares of the medical equipment provider’s stock worth $34,000 after acquiring an additional 1,000 shares during the last quarter. Bessemer Group Inc. increased its holdings in shares of Smith & Nephew SNATS by 3,471.4% in the 1st quarter. Bessemer Group Inc. now owns 1,750 shares of the medical equipment provider’s stock worth $49,000 after acquiring an additional 1,701 shares during the period. Banque Transatlantique SA bought a new stake in Smith & Nephew SNATS in the 1st quarter valued at about $52,000. Finally, Opal Wealth Advisors LLC acquired a new position in Smith & Nephew SNATS during the 1st quarter valued at about $73,000. 25.64% of the stock is currently owned by institutional investors and hedge funds.

Smith & Nephew SNATS Stock Performance

SNN opened at $35.44 on Monday. The business has a 50 day moving average price of $35.65 and a two-hundred day moving average price of $30.97. The company has a debt-to-equity ratio of 0.60, a current ratio of 3.00 and a quick ratio of 1.40. The company has a market capitalization of $15.43 billion, a price-to-earnings ratio of 16.41, a price-to-earnings-growth ratio of 0.98 and a beta of 0.70. Smith & Nephew SNATS, Inc. has a 1-year low of $23.69 and a 1-year high of $38.79.

Smith & Nephew SNATS Cuts Dividend

The company also recently announced a semi-annual dividend, which will be paid on Friday, November 7th. Investors of record on Friday, October 3rd will be paid a dividend of $0.285 per share. The ex-dividend date of this dividend is Friday, October 3rd. This represents a yield of 210.0%. Smith & Nephew SNATS’s dividend payout ratio (DPR) is currently 41.20%.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. Canaccord Genuity Group lifted their price target on Smith & Nephew SNATS from $28.00 to $36.00 and gave the company a “hold” rating in a report on Monday, August 18th. Wall Street Zen upgraded Smith & Nephew SNATS from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 30th. Six research analysts have rated the stock with a Hold rating, According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $36.00.

About Smith & Nephew SNATS

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.